Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERMAX vs BROMOCRIPTINE MESYLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Parkinson's disease,Hyperprolactinemia
FDA-approved: Treatment of hyperprolactinemia (including amenorrhea/galactorrhea, hypogonadism, infertility) associated with prolactin-secreting adenomas,FDA-approved: Adjunctive treatment of Parkinson disease (idiopathic or postencephalitic),FDA-approved: Treatment of acromegaly (as an adjunct to surgery or radiotherapy),Off-label: Type 2 diabetes mellitus (improves glycemic control),Off-label: Neuroleptic malignant syndrome,Off-label: Prevention of postpartum lactation (use not recommended due to serious adverse events)
Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
Terminal elimination half-life: 27 hours (range 24-30 hours) in healthy adults; significantly prolonged in renal impairment (up to 100+ hours in ESRD), requiring dose adjustment.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Hepatic (CYP3A4, CYP1A2); extensive first-pass metabolism.
Extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) to multiple metabolites, including the major active metabolite 2-bromo-α-ergocriptine. Also undergoes non-CYP-mediated hydrolysis and conjugation. First-pass metabolism is significant, resulting in ~6% oral bioavailability.
Renal: ~50% unchanged drug; biliary/fecal: ~40% as metabolites and parent drug; total clearance approximates hepatic blood flow.
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
~90% bound to plasma proteins (primarily albumin).
90-96% bound to serum albumin, with some binding to alpha-1-acid glycoprotein.
Vd: 6-8 L/kg (central compartment ~0.5 L/kg), indicating extensive tissue distribution.
Approximately 2-3 L/kg, indicating extensive tissue distribution and penetration into breast milk and central nervous system.
Oral: ~50% (range 30-70%) due to first-pass hepatic metabolism; food does not significantly affect absorption.
Oral: 28-30% due to extensive first-pass metabolism; sublingual: 40-50% due to partial avoidance of hepatic first-pass; rectal: approximately 20%.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No specific dose adjustment recommended; monitor for accumulation in severe renal impairment (e GFR <30 m L/min).
Child-Pugh Class A: use with caution, consider dose reduction; Child-Pugh Class B or C: contraindicated.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Safety and efficacy not established; no approved pediatric dosing.
Prolactinomas: 1.25-2.5 mg/m²/day orally in 2-3 divided doses; titrate based on response. Weight-based: 0.01-0.02 mg/kg/day, increase slowly.
Start at low end of dosing range (0.05 mg once daily); titrate slowly due to increased risk of hypotension and hallucinations.
Initiate at low end of dosing range (1.25 mg once or twice daily) due to increased sensitivity and risk of hypotension; titrate slowly.
None.
None
May cause valvular heart disease; fibrotic complications (pleural, pericardial, peritoneal); sudden sleep onset; orthostatic hypotension; hallucinations; impulse control disorders; dopamine agonist withdrawal syndrome.
May cause hypotension (especially postural), syncope, and severe adverse reactions such as myocardial infarction, stroke, seizures, and psychosis. Can cause pleural and retroperitoneal fibrosis, pericarditis, and valvulopathy (especially with high doses for Parkinson disease). Has been associated with pathological gambling, hypersexuality, and impulse control disorders. May cause somnolence and sudden sleep onset. Monitor for cardiac valvulopathy and pulmonary fibrosis. Use with caution in patients with cardiovascular disease, peptic ulcer disease, or a history of mental illness.
Hypersensitivity to pergolide; ergot alkaloid allergy; history of cardiac valvulopathy.
Absolute: Hypersensitivity to bromocriptine or ergot alkaloids; uncontrolled hypertension; pregnancy (toxemia of pregnancy); preeclampsia/eclampsia; coronary artery disease or other significant cardiovascular disease; severe renal or hepatic impairment. Relative: History of peptic ulcer disease, psychiatric disorders, Raynaud phenomenon, or hepatic impairment.
No specific food interactions documented. However, high-protein meals may reduce absorption; take consistently with or without food. Avoid alcohol due to additive CNS depression.
Take with food to reduce gastrointestinal irritation; avoid high-protein meals if using for hyperprolactinemia as protein may decrease absorption.
Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women exist. First trimester: theoretical risk due to dopamine agonist activity; second/third trimester: limited data, risk of postpartum hemorrhage due to ergot alkaloid properties. Use only if benefit outweighs risk.
First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage due to uterine atony; may suppress pituitary prolactin, potentially impairing placental lactogen production. Overall, use only if clearly needed.
Pergolide suppresses lactation by inhibiting prolactin secretion. It is excreted in human breast milk; M/P ratio not established. Contraindicated in breastfeeding women due to potential for dopamine receptor stimulation in infant and suppression of lactation.
Bromocriptine suppresses lactation by inhibiting prolactin secretion. It is contraindicated in breastfeeding women due to the intended suppression of milk production. No M/P ratio available; minimal excretion into breast milk is expected but not well studied.
No specific dose adjustment guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce serum levels, but efficacy and safety data are lacking. Use lowest effective dose if unavoidable. Avoid postpartum due to lactation suppression effects.
No specific dose adjustments are recommended for pregnancy; however, the drug is generally discontinued once pregnancy is confirmed unless necessary for prolactinoma treatment. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may theoretically alter levels, but data are insufficient to recommend dose changes.
Permax (pergolide) is a dopamine receptor agonist used for Parkinson's disease. Due to risk of valvular heart disease, it is withdrawn from the US market; use only in exceptional cases with echocardiogram monitoring. Titrate slowly to avoid orthostatic hypotension. May cause sudden sleep episodes; advise patients not to drive. Do not abruptly discontinue (risk of neuroleptic malignant syndrome).
Titrate slowly to minimize orthostatic hypotension and gastrointestinal upset. Administer with food to reduce nausea. Monitor for pulmonary fibrosis and Raynaud phenomenon with long-term use. Avoid concomitant use with ergot alkaloids due to additive vasospasm risk.
Take exactly as prescribed; do not stop suddenly without consulting doctor.,May cause dizziness, especially when standing up; rise slowly and avoid sudden position changes.,Can cause sudden sleepiness; do not drive or operate machinery until you know how the drug affects you.,Report any new or worsening heart palpitations, shortness of breath, or swelling in ankles/feet.,Avoid alcohol as it may increase dizziness and drowsiness.
Take with food to reduce nausea and lightheadedness.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol as it may worsen side effects.,Report persistent cough, chest pain, or changes in urination or vision.,Do not stop abruptly; taper under medical supervision.
No interactions on record
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Concurrent use of bromocriptine, a dopamine D2 receptor agonist, and enasidenib, an IDH2 inhibitor, may lead to increased risk of central nervous system adverse effects, including dizziness, somnolence, and extrapyramidal symptoms. Enasidenib inhibits CYP3A4, which metabolizes bromocriptine, potentially elevating bromocriptine plasma concentrations. This pharmacokinetic interaction can exacerbate dopaminergic toxicity, especially in patients with hepatic impairment or those on high-dose bromocriptine."
"Bromocriptine, a dopamine D2 receptor agonist and ergot derivative, is primarily metabolized by CYP3A4. Astemizole, a second-generation antihistamine, is also metabolized by CYP3A4. Concomitant use of these two drugs can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of both agents. Elevated bromocriptine levels raise the risk of ergotism (vasospasm, ischemia) and neuropsychiatric toxicities, while increased astemizole concentrations may prolong the QT interval, predisposing patients to life-threatening ventricular arrhythmias such as torsades de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERMAX vs BROMOCRIPTINE MESYLATE, answered by our medical review team.
PERMAX is a Dopamine Agonist that works by Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.. BROMOCRIPTINE MESYLATE is a Dopamine Agonist that works by Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERMAX and BROMOCRIPTINE MESYLATE depend on the specific clinical indication. These are both Dopamine Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERMAX is: Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.. The standard adult dose of BROMOCRIPTINE MESYLATE is: Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERMAX and BROMOCRIPTINE MESYLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERMAX is classified as Category C. Pergolide (PERMAX) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but no adequate, well-controlled studies in pregnant women ex. BROMOCRIPTINE MESYLATE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.